Pay in 4 interest-free payments of $6.24 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Patients should be educated on gastrointestinal side effects at treatment initiation
Tirzepatide is a dual-action medication that targets both GLP-1 and GIP receptors, which is why clinical trials have shown it producing greater average weight loss than semaglutide alone
Chrousos, G
C., Qu, H., Loghin, C., Moyers, J
In real-world practice, a SGLT2i and a GLP-1RA are more likely to be initiated sequentially rather than simultaneously, not only for economic reasons but also to improve medication adherence [1]
As the product is not sold in retail stores or major marketplaces, availability depends entirely on the company's website
US$ 25.36
US$ 23.17
US$ 21.12
US$ 24.86
